title: The perspective of caffeine and caffeine derived compounds in therapy.
abstract: Caffeine (1,3,7-trimethylxanthine) is a plant secondary metabolite with a significant impact on multiple processes and regulatory pathways in the body. Though major part of the population meets caffeine via coffee, tea or chocolate, it has also an important role in pharmacology and it is used as a supplementary substance in medicaments. Currently, the ability of caffeine to ameliorate some neurodegenerative disorders is proved in some studies. This review describes basic data about caffeine including toxicity, pharmacokinetics, biological mechanism of the action, and metabolism. Beside this, promising applications of caffeine, new medicaments and derivatives are discussed. Relevant papers and inventions are depicted in the manuscript. Caffeine is a pharmacologically promising substance that deserves big consideration in the current research and development. The compound has several reasons to be an object of scientific interest and to be used for pharmacology purposes. Despite an extensive research for a long time, no significantly negative effects on human health were proved hence caffeine can be considered as a completely safe compound. The recent data about amelioration of neurodegenerative and other disorders are promising and deserving more work on the issue. ARTICLE HIGHLIGHTS: Caffeine is a purine alkaloid from plants and it has a broad use in current pharmacology. Caffeine is a competitive antagonist of neurotransmitter adenosine on adenosine receptors. The substance is added as a supplementary to drugs and food.Besides interfering on adenosine receptors, caffeine interacts with acetylcholinesterase, monoamine oxidase, phosphodiesterase, ryanodine receptors and others.Current research is devoted to the role of caffeine in neurodegenerative diseases and immunity alteration. New chemical compounds based on caffeine moiety are prepared (Tab. 4, Fig. 6, Ref. 149).
authors.forename: M
authors.initials: M
authors.lastname: Pohanka
mesh_terms: D000110:Acetylcholinesterase / Q000187:drug effects*; D000470:Alkaloids / Q000494:pharmacology; D001921:Brain / Q000187:drug effects*; D002110:Caffeine / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008995:Monoamine Oxidase / Q000187:drug effects*; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000470:Alkaloids; D010726:Phosphodiesterase Inhibitors; D058915:Purinergic P1 Receptor Antagonists; D002110:Caffeine; D008995:Monoamine Oxidase; D000110:Acetylcholinesterase
keywords: Alzheimer disease; GABA; Parkinson disease; adenosine; caffeine; dopamine; immunity; theobromine.; theophylline